252 related articles for article (PubMed ID: 29038296)
1. A Blueprint to Advance Colorectal Cancer Immunotherapies.
Le DT; Hubbard-Lucey VM; Morse MA; Heery CR; Dwyer A; Marsilje TH; Brodsky AN; Chan E; Deming DA; Diaz LA; Fridman WH; Goldberg RM; Hamilton SR; Housseau F; Jaffee EM; Kang SP; Krishnamurthi SS; Lieu CH; Messersmith W; Sears CL; Segal NH; Yang A; Moss RA; Cha E; O'Donnell-Tormey J; Roach N; Davis AQ; McAbee K; Worrall S; Benson AB
Cancer Immunol Res; 2017 Nov; 5(11):942-949. PubMed ID: 29038296
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for the treatment of colorectal cancer.
Lumish MA; Cercek A
J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
[TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
Wang D; Zhang H; Xiang T; Wang G
Front Immunol; 2021; 12():762341. PubMed ID: 34721435
[TBL] [Abstract][Full Text] [Related]
4. [Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden].
Cohen R; Heran M; Pudlarz T; Hilmi M; Tournigand C; André T; Rousseau B
Bull Cancer; 2019 Feb; 106(2):151-161. PubMed ID: 30638897
[TBL] [Abstract][Full Text] [Related]
5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
6. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy.
Keenan BP; VAN Loon K; Khilnani AD; Fidelman N; Behr SC; Atreya CE; Oh DY
Anticancer Res; 2021 Jun; 41(6):2985-2992. PubMed ID: 34083289
[TBL] [Abstract][Full Text] [Related]
8. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
[No Abstract] [Full Text] [Related]
9. The colorectal cancer immune microenvironment and approach to immunotherapies.
Koi M; Carethers JM
Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193
[No Abstract] [Full Text] [Related]
10. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
11. [Development of immune checkpoint inhibitor in colorectal cancer].
Kitano S
Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
[TBL] [Abstract][Full Text] [Related]
12. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
13. T-cell-based immunotherapy in colorectal cancer.
Feng M; Zhao Z; Yang M; Ji J; Zhu D
Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
[TBL] [Abstract][Full Text] [Related]
14. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
Boland CR; Thibodeau SN; Hamilton SR; Sidransky D; Eshleman JR; Burt RW; Meltzer SJ; Rodriguez-Bigas MA; Fodde R; Ranzani GN; Srivastava S
Cancer Res; 1998 Nov; 58(22):5248-57. PubMed ID: 9823339
[TBL] [Abstract][Full Text] [Related]
15. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and patients treated for cancer with microsatellite instability.
Colle R; Cohen R; Cochereau D; Duval A; Lascols O; Lopez-Trabada D; Afchain P; Trouilloud I; Parc Y; Lefevre JH; Fléjou JF; Svrcek M; André T
Bull Cancer; 2017 Jan; 104(1):42-51. PubMed ID: 27979364
[TBL] [Abstract][Full Text] [Related]
17. Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers.
Chang L; Chang M; Chang HM; Chang F
J Gastrointest Cancer; 2017 Dec; 48(4):305-313. PubMed ID: 28699072
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
19. The potential role of immunotherapy to treat colorectal cancer.
Amin M; Lockhart AC
Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathological classification of colorectal cancer.
Müller MF; Ibrahim AE; Arends MJ
Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
